Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma

YASUHIRO CHIKAISHI, HIDETAKA URAMOTO and FUMIHIRO TANAKA
Anticancer Research December 2011, 31 (12) 4451-4456;
YASUHIRO CHIKAISHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDETAKA URAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hidetaka{at}med.uoeh-u.ac.jp
FUMIHIRO TANAKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Kaplan-Meier (disease-free survival) curves stratified by the expression of EMT-related molecules. The heavy and dotted lines indicate positive and negative expression of EMT-related molecules, respectively. A: The 5-year DFS rates in patients with negative and positive E-cadherin expression were 89.1% and 82.0% (p=0.183), respectively. B: The 5-year DFS rates in patients with negative and positive gamma catenin expression were 80.7% and 68.1% (p=0.845), respectively. C: The 5-year DFS rates in patients with negative and positive gamma-catenin expression were 76.7% and 67.9% (p=0.452), respectively.

Tables

  • Figures
  • Table I.
  • Table II.
  • Table III.
  • Table IV.
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 31, Issue 12
December 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma
YASUHIRO CHIKAISHI, HIDETAKA URAMOTO, FUMIHIRO TANAKA
Anticancer Research Dec 2011, 31 (12) 4451-4456;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma
YASUHIRO CHIKAISHI, HIDETAKA URAMOTO, FUMIHIRO TANAKA
Anticancer Research Dec 2011, 31 (12) 4451-4456;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
  • Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer
  • Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma
  • Clinical significance of E-cadherin, {beta}-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma
  • Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non-Small-Cell Lung Cancer
  • Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI
  • Prediction of Recurrence after Complete Resection in Patients with NSCLC
  • Google Scholar

More in this TOC Section

  • Short-term and Long-term Outcomes of Prophylactic Corticosteroid in Esophageal Cancer Surgery: A Multicenter Retrospective Study
  • Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer
  • Body Weight Loss at Recurrence as an Independent Prognostic Factor in Patients With Recurrent Esophageal Cancer After Esophagectomy Who Receive First-line Treatment After Recurrence
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire